{"nctId":"NCT02263131","briefTitle":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children","startDateStruct":{"date":"2013-10"},"conditions":["Healthy"],"count":416,"armGroups":[{"label":"IL-YANG PFS","type":"EXPERIMENTAL","interventionNames":["Biological: IL-YANG FLU Vaccine Prefilled Syringe INJ."]},{"label":"TIV PFS","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: VAXIGRIP Prefilled Syringe INJ."]}],"interventions":[{"name":"IL-YANG FLU Vaccine Prefilled Syringe INJ.","otherNames":[]},{"name":"VAXIGRIP Prefilled Syringe INJ.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men or women aged from 6 months to \\< 18 years\n* Subjects were born after full term pregnancy (37 weeks)\n* Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 10 years of age (and for subjects younger than 7 years of age for the some institutions)).\n\nExclusion Criteria:\n\n* Subject with a known allergy to eggs, chicken, neomycin, gentamicin or any components of the study vaccine\n* Subject who had received an influenza vaccine within the last 6 months\n* Subject who has, or has a family history of, an immune system disorder including immune deficiency disease\n* Subject with a history of Guillain-Barre syndrome\n* Subject with Down's syndrome or cytogenetic disorders.\n* Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial\n* Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection\n* Subject who had an acute fever with body temperature \\> 38.0 Cº within 72 hours prior to administration of the study vaccine\n* Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.\n* Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine\n* Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.\n* Subject who had participated in another experimental study within 30 days prior to administration of the study vaccine\n* Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion","description":"Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer \\< 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.02","spread":null},{"groupId":"OG001","value":"76.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.41","spread":null},{"groupId":"OG001","value":"57.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.90","spread":null},{"groupId":"OG001","value":"66.18","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Achieving Seroconversion for HI Antibody After Administration of the Study Vaccine Depending of the Number of Vaccination","description":"Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer \\< 1:10 and a post-vaccination (last vaccination + Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (last vaccination + Day 28) HI antibody titer (Case 2),","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.06","spread":null},{"groupId":"OG001","value":"54.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.76","spread":null},{"groupId":"OG001","value":"66.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.41","spread":null},{"groupId":"OG001","value":"56.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.86","spread":null},{"groupId":"OG001","value":"66.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.22","spread":null},{"groupId":"OG001","value":"66.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.07","spread":null},{"groupId":"OG001","value":"66.67","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate for HI Antibody","description":"Percentage of Participants With Healthy Children Aged From 6 Months to \\<18 Years With Seroprotection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.96","spread":null},{"groupId":"OG001","value":"89.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.77","spread":null},{"groupId":"OG001","value":"91.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.25","spread":null},{"groupId":"OG001","value":"95.59","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate of HI Antibody","description":"Percentage of subjects achieving seroprotection for HI antibody after administration of the study vaccine depending of the number of vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.10","spread":null},{"groupId":"OG001","value":"91.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.76","spread":null},{"groupId":"OG001","value":"66.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.45","spread":null},{"groupId":"OG001","value":"93.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.86","spread":null},{"groupId":"OG001","value":"66.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.75","spread":null},{"groupId":"OG001","value":"96.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.31","spread":null},{"groupId":"OG001","value":"83.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer* (GMT) of HI Antibody","description":"Geometric Mean Titer (GMT), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.40","spread":null},{"groupId":"OG001","value":"24.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.40","spread":null},{"groupId":"OG001","value":"88.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.85","spread":null},{"groupId":"OG001","value":"30.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.60","spread":null},{"groupId":"OG001","value":"104.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.22","spread":null},{"groupId":"OG001","value":"39.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130.53","spread":null},{"groupId":"OG001","value":"151.70","spread":null}]}]}]},{"type":"SECONDARY","title":"GMR of HI Antibody Titer Before Vaccination and After Vaccination","description":"Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.57","spread":null},{"groupId":"OG001","value":"3.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":null},{"groupId":"OG001","value":"3.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":null},{"groupId":"OG001","value":"3.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer < 1:40, Minimum Four-fold Rise in Post-vaccination (Day 28) HI Antibody Titer","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.29","spread":null},{"groupId":"OG001","value":"28.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.90","spread":null},{"groupId":"OG001","value":"50.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.75","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":347},"commonTop":["Tenderness","Pain","Redness","Swelling"]}}}